COMPARE - Pediatric Inflammatory Bowel Disease (PIBD)
NCT07198113
This study is recruiting at 4 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of the study is to compare the clinical effectiveness and safety of newer inflammatory bowel disease (IBD) medications in anti-tumor necrosis factor (TNF) refractory patients with pediatric IBD (PIBD). Refractory means that there was no clinical response to anti-tumor necrosis factor (TNF) drugs or that the if there was a response, it is no longer present. The main question this study aims to answer is: Are the newer medications used to treat IBD just as safe and effective for treating IBD in children.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Ulcerative Colitis, Pediatric
- Inflammatory Bowel Diseases
- Crohn Disease
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 1 year to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- University of North Carolina, Chapel Hill
- Last updated on ClinicalTrials.gov
- April 17, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
North Carolina · 3
- University of North Carolina at Chapel Hill · Chapel Hill, NC
- Atrium Health · Charlotte, NC
- Duke Health System · Durham, NC
Pennsylvania · 1
- University of Pittsburgh Medical Center, Children's Hospital · Pittsburgh, PA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.